Cantuzumab ravtansine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cantuzumab ravtansine
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NYesY (what is this?)  (verify)

Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).[1] It uses a more hindered disulfide linkage than cantuzumab mertansine.[2]

See also[edit]

References[edit]

  1. ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2). 
  2. ^ Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to ...